Vetmedin Chewable Tablets for Dogs

Warnings

Only for use in dogs with clinical evidence of heart failure. At 3 and 5 times the recommended dosage, administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology.

Precautions

The safety of Vetmedin has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than AVVI or DCM. The safe use of Vetmedin has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or those who are pregnant or lactating.

Vetmedin should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

Food and Drug Interactions

Vetmedin is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

Human Warnings

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans.

Possible Side Effects

The most commonly reported side effects of VETMEDIN were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. The prevalence of side effects was similar in the active control group.

Contact your veterinarian if you believe your pet is experiencing side effects.

Product Administration

Oral

Product Form

Chewable Tablet

Ingredients

Pimobendan

Storage

Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).

Manufacturer

Boehringer Ingelheim

Prescribing Info/Brochures

• https://www.bi-vetmedica.com/sites/default/files/dam/internet/ah/vetmedica/com_EN/product_files/vetmedin/Vetmedin_ProductInformation.pdf